- Reference code :
- wf360
- Published date :
-
17 November 2000
- Expired date :
-
04 April 2028
AstraZeneca today announced that the Stockholm District Court has ruled that Scand Pharm's generic omeprazole product infringes AstraZeneca's Supplementary Patent Certificate (SPC) for omeprazole, which provides protection until November 15, 2002.
Omeprazole is the active ingredient in Losec®, a treatment for stomach acid disorders.
The judgement follows an earlier preliminary injunction granted to AstraZeneca.
Dr. Martin Nicklasson, Executive Vice-President of AstraZeneca's GI Franchise, said: "We are delighted by this judgement, which confirms our opinion that the SPC for omeprazole is in force and prevents generic omeprazole products from entering the market."
In 1999, Losec MUPS®, had sales of $90m in Sweden, representing 1.5 per cent of total sales of the product.
The substance patent for omeprazole in Sweden expired in April, 1999. A decision is pending on AstraZeneca's appeal against a ruling by the Swedish Patent and Registration Office (PRV) that an SPC, granted under Swedish law, had lapsed due to the surrender of marketing authorisation for Losec® capsules.
AstraZeneca has also filed a main action for infringement of the formulation patent for omeprazole against Scand Pharm.
Further enquires to:
|
Steve Brown +44 (0)20 7304 5033 Lucy Williams +44 (0)20 7304 5034 |
Not signed in
Page tools
Share price
- London
-
26.95 GBP - New York
-
44.82 USD
- Stockholm
-
310.10 SEK
At 21-Nov-2009 05:36 GMT
Detailed share priceIntroduction to AstraZeneca
Our responsibility
We continue to communicate openly on a range of issues, including:
